Assay News and Research

RSS

STE90-C11, a SARS-CoV-2 neutralizing antibody, shows high inhibition of RBD-ACE2 binding

In a new study, researchers describe the identification of a neutralizing antibody that binds to the RBD at the same site as the human host cell receptor.

7 Dec 2020

High-performance ELISA for serology in mild-moderate non-hospitalized COVID-19

A new study describes an ELISA assay that combines the detection of IgM, IgA, and IgG antibodies against the SARS−CoV−2 trimeric spike glycoprotein.

7 Dec 2020

CRISPR-based test could provide rapid, low-cost testing to help control COVID-19 spread

Imagine swabbing your nostrils, putting the swab in a device, and getting a read-out on your phone in 15 to 30 minutes that tells you if you are infected with the COVID-19 virus.

5 Dec 2020

Mysterious particle found in the blood of people with sepsis

Researchers at La Jolla Institute for Immunology have found that people with sepsis have never-before-seen particles in their blood.

5 Dec 2020

SARS-CoV-2 D614G mutation does not affect performance of serological assays

In a new study published in The Journal of Infectious Diseases, US researchers considered the emergence of a new SARS-CoV-2 spike protein variant. They compared spike G614-based assay to the original D614-based assay – pointing towards the development of recognizable, cross-responsive humoral immunity.

2 Dec 2020

SARS-CoV-2 deletion mutations may have attenuated infectivity in some strains

A team of researchers at the University of Hong Kong has identified a panel of SARS-CoV-2 variants, called Del-mut, which contains a deletion in the S1/S2 junction. Upon investigating one of the deleted variants in animal models, they found that Del-mut-1 is attenuated in its ability to cause disease or pathological changes.

2 Dec 2020

Potential SARS-CoV-2 antiviral: Ionophore X-206 found to inhibit viral replication in cell cultures

In a study published in the journal Antiviral Research, researchers from Aarhus University, Denmark, report on their tests on different polyether ionophores to inhibit SARS-CoV-2 in vitro.

1 Dec 2020

Good cholesterol helps SARS-CoV-2 enter cells

The researchers explained that the SARS-CoV-2 can infect human host cells after its viral spike protein (SARS-2-S) binds to a cellular surface receptor called the angiotensin-converting enzyme 2 (ACE2).

30 Nov 2020

Chemical compounds in foods can block the function of key SARS-CoV-2 enzyme

Chemical compounds in foods or beverages like green tea, muscadine grapes and dark chocolate can bind to and block the function of a particular enzyme, or protease, in the SARS-CoV-2 virus, according to a new study by plant biologists at North Carolina State University.

30 Nov 2020

HIV and TB laboratory systems used to scale up COVID-19 testing in Africa

Many countries in resource-limited settings have high HIV, malaria, tuberculosis, hepatitis, and/or sexually transmitted infection (STI) burdens.

30 Nov 2020

Resveratrol shows potential as SARS-CoV-2 antiviral, study finds

A recent study reveals that resveratrol, a phenolic compound produced by spermatophytes, can inhibit the viral replication SARS-CoV-2.

27 Nov 2020

Ipom-F inhibits SARS-CoV-2 infection in vitro

An international team of researchers showed the small molecule inhibitor, ipomoeassin F (Ipom-F), blocks the translocation/insertion of the three protein targets for SARS-CoV-2 infection.

27 Nov 2020

Siemens Healthineers SARS-CoV-2 IgG antibody test demonstrates ability to detect neutralizing antibodies

Siemens Healthineers has announced its SARS-CoV-2 IgG Antibody Test has proven to measure neutralizing antibodies and has achieved CE Mark. The test is an enhanced version of the assay which became available globally this summer.

From Siemens Healthineers 27 Nov 2020

Body mass index and severe COVID-19

French researchers led by first author Abdallah Al-Salameh from the Department of Endocrinology, Diabetes Mellitus and Nutrition, Amiens University Hospital, Amiens, France, have published findings of their study titled, “The association between body mass index class and coronavirus disease 2019 outcomes,” in the latest issue of the International Journal of Obesity.

26 Nov 2020

SARS-CoV-2 spike protein antibodies can persist up to 200 days after symptom onset

Researchers report SARS-CoV-2 antibodies to the spike protein (S protein) can persist 200 days after symptom onset, but that antibodies to the nucleoprotein (N protein) can reduce much more rapidly.

25 Nov 2020

Is COVID-19 severity mediated by higher antibody response?

A new study indicates that patients with more severe COVID-19 have a stronger antibody response.

25 Nov 2020

Widely used antibiotic shows promise for fighting against Zika infections

In 2015, hundreds of children were born with brain deformities resulting from a global outbreak of Zika virus infections.

24 Nov 2020

Mefloquine shows potential as anti-SARS-CoV-2 drug

A team of scientists from Japan has identified the approved anti-material drug, mefloquine, as a potential candidate to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Specifically, mefloquine has been shown to prevent the entry of SARS-CoV-2 into host cells and reduce the viral load in vitro.

24 Nov 2020

Digital warm-start CRISPR assay enables sensitive quantitative detection of SARS-CoV-2 in clinical samples

In a recent medRxiv* preprint paper, researchers from the University of Connecticut Health Center in the United States unveil their digital warm-start CRISPR (WS-CRISPR) method for stringent and sensitive quantitative detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in clinical samples of patients with coronavirus disease (COVID-19).

24 Nov 2020

Scientists show SARS-CoV-2's viral replication with 3D integrative imaging

A team of researchers at Heidelberg University in Germany have performed a detailed imaging analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to determine how the virus reprograms infected cells.

24 Nov 2020